Local tumour control and patient survival after ruthenium-106 brachytherapy for small choroidal melanoma.

Aim: To report local tumour control, metastasis and survival rates of patients with small choroidal melanoma (CM) after treatment with ruthenium-106 (Ru-106) plaque brachytherapy.

Methods: Retrospective case series of 353 consecutive eyes with small CM (thickness ≤2.5 mm and largest basal diameter ≤16 mm) treated with Ru-106 brachytherapy at the London Ocular Oncology Service, between October 2004 and May 2019.

The incidence and prevalence of recurrent corneal erosion syndrome in London, UK.

Background: Recurrent corneal erosion syndrome (RCES) is caused by repeated episodes of corneal epithelial breakdown due to improper adherence of the corneal epithelium to the underlying basement membrane. The most common aetiologies are corneal dystrophy or previous superficial ocular trauma. The incidence and prevalence of the condition is currently unknown.

Patient and clinician perspectives of ophthalmology emergency attendances during the COVID 19 pandemic.

Introduction: To explore patient and clinician perspectives on acute ophthalmology presentations during the COVID pandemic. To ascertain whether the pandemic had differentially impacted access to care based on patient demographics and postcodes.

Methods: A single-centre, cross-sectional prospective study in a busy metropolitan eye casualty between April-June 2020 recording patient demographics, distance travelled to access healthcare, diagnosis and outcome compared to the equivalent period in 2019.

Correction: Impact of COVID-19 on ophthalmic specialist training in the United Kingdom-the trainees' perspective.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Effect of glycosylated hemoglobin on response to ranibizumab therapy in diabetic macular edema: real-world outcomes in 312 patients.

Objective: To investigate the effect of serum glycosylated hemoglobin (HbA1c) on the outcomes of ranibizumab therapy for diabetic macular edema (DME).

Design: Retrospective cohort study.

Participants: Patients receiving ranibizumab injections for centre-involving DME in a National Health Service setting.